ReviewRegenerative medicine2012
Functional cardiac tissue engineering.
Review in Regenerative medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Towards chamber specific heart-on-a-chip for drug testing applications.Advanced drug delivery reviews · 2020Pooled it
- CITED Proteins in Cardiac Development and Lifelong Heart Function.Journal of personalized medicine · 2025Review
- Development, in vitro, and in vivo assessments of PCL-gelatin-βTCP fibrous scaffolds for cardiac regeneration.BioImpacts : BI · 2025Article
- Insights into the prospects of nanobiomaterials in the treatment of cardiac arrhythmia.Journal of nanobiotechnology · 2024Review
- Striated preferentially expressed gene deficiency leads to mitochondrial dysfunction in developing cardiomyocytes.Basic research in cardiology · 2024Article
- Article
- Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration.Cardiovascular research · 2022Review
- Modelling the interaction between stem cells derived cardiomyocytes patches and host myocardium to aid non-arrhythmic engineered heart tissue design.PLoS computational biology · 2022Article
- Electroconductive biomaterials for cardiac tissue engineering.Acta biomaterialia · 2022Review
- Mesenchymal Stem Cells for Cardiac Regeneration: from Differentiation to Cell Delivery.Stem cell reviews and reports · 2021Review
- Translational Studies on the Potential of a VEGF Nanoparticle-Loaded Hyaluronic Acid Hydrogel.Pharmaceutics · 2021Article
- Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies.Biomedicines · 2021Review
- Engineering and Assessing Cardiac Tissue Complexity.International journal of molecular sciences · 2021Review
- Uniformly-aligned gelatin/polycaprolactone fibers promote proliferation in adipose-derived stem cells and have distinct effects on cardiac cell differentiation.International journal of clinical and experimental pathology · 2021Article
- Metabolic Regulation of Human Pluripotent Stem Cell-Derived Cardiomyocyte Maturation.Current cardiology reports · 2020Review
- Lack of Thy1 defines a pathogenic fraction of cardiac fibroblasts in heart failure.Biomaterials · 2020Article
- Mending a broken heart: current strategies and limitations of cell-based therapy.Stem cell research & therapy · 2020Review
- Practical adoption of state-of-the-art hiPSC-cardiomyocyte differentiation techniques.PloS one · 2020Article
- Engineering a naturally-derived adhesive and conductive cardiopatch.Biomaterials · 2019Article
- Generation of bioartificial hearts using decellularized scaffolds and mixed cells.Biomedical engineering online · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Heart attack remains the leading cause of death in both men and women worldwide. Stem cell-based therapies, including the use of engineered cardiac tissues, have the potential to treat the massive cell loss and pathological remodeling resulting from heart attack. Specifically, embryonic and induced pluripotent stem cells are a promising source for generation of therapeutically relevant numbers of functional cardiomyocytes and engineering of cardiac tissues in vitro. This review will describe methodologies for successful differentiation of pluripotent stem cells towards the cardiovascular cell lineages as they pertain to the field of cardiac tissue engineering. The emphasis will be placed on comparing the functional maturation in engineered cardiac tissues and developing heart and on methods to quantify cardiac electrical and mechanical function at different spatial scales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.